Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

INO Inovio Pharmaceuticals, Inc.
$1.70 0.59% +0.01
Notify me if price changes either direction
Interactive Brokers Logotype

Buy INO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 116.5M
Enterprise value 49.8M
Trailing PE -0.42911393732964
Forward PE -1.162311
PEG Ratio 0.19095570211169
Enterprise to EBITDA -0.564
Enterprise to revenue 272.864
Price to book MRQ -11.454171309883
Price to sales TTM 636.7809

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 182.3K
EBITDA -88220528
Diluted EPS TTM -2.72
Total Cash (MRQ) 50.8M
Current ratio (MRQ) 0.79
Operating Cash Flow (TTM) -88922792

INO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent INO News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.